Rating Change
BMO Capital analysts initiated coverage on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) with a rating of Outperform on August 19, 2026.
new coverageNASDAQ:BCAX
BMO Capital Initiates Coverage on Bicara Therapeutics Inc. Common Stock (BCAX) with Outperform
BMO Capital analysts initiated coverage on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) with a rating of Outperform on August 19, 2026.
At publication ·
What changed
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) · new coverage
- Firm
- BMO Capital
- Rating
- Outperform
- Price at event
- $25.86
- Market capitalization
- $1.0B
At a glance
Key takeaways
- BMO Capital initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating on August 19, 2026, as the healthcare stock trades at $25.86 with a $1.0B market capitalization.
Market Context
Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $25.86 with a market capitalization of $1.0B. The stock has gained 114.1% over the past 52 weeks.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bicara Therapeutics Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bicara Therapeutics Inc. Common Stock
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | N/A |
| Aug 12, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 12, 2026 | Wedbush | Outperform | N/A |
| Aug 12, 2026 | Goldman Sachs | Neutral | N/A |
| Aug 12, 2026 | Mizuho | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View BCAX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for BCAX?
A rating of Outperform from BMO Capital reflects the analyst's outlook on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BCAX forecast page.